Literature DB >> 25288514

Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test.

Min Feng1, Jun Gao, Nan Sui, Ming Li.   

Abstract

RATIONALE: Acute administration of clozapine (a gold standard of atypical antipsychotics) disrupts avoidance response in rodents, while repeated administration often causes a tolerance effect.
OBJECTIVE: The present study investigated the neuroanatomical basis and receptor mechanisms of acute and repeated effects of clozapine treatment in the conditioned avoidance response test in male Sprague-Dawley rats.
METHODS: 2,5-dimethoxy-4-iodo-amphetamine (DOI, a preferential 5-HT2A/2C agonist) or quinpirole (a preferential dopamine D2/3 agonist) was microinjected into the medial prefrontal cortex (mPFC) or nucleus accumbens shell (NAs), and their effects on the acute and long-term avoidance disruptive effect of clozapine were tested.
RESULTS: Intra-mPFC microinjection of quinpirole enhanced the acute avoidance disruptive effect of clozapine (10 mg/kg, sc), while DOI microinjections reduced it marginally. Repeated administration of clozapine (10 mg/kg, sc) daily for 5 days caused a progressive decrease in its inhibition of avoidance responding, indicating tolerance development. Intra-mPFC microinjection of DOI at 25.0 (but not 5.0) μg/side during this period completely abolished the expression of clozapine tolerance. This was indicated by the finding that clozapine-treated rats centrally infused with 25.0 μg/side DOI did not show higher levels of avoidance responses than the vehicle-treated rats in the clozapine challenge test. Microinjection of DOI into the mPFC immediately before the challenge test also decreased the expression of clozapine tolerance.
CONCLUSIONS: Acute behavioral effect of clozapine can be enhanced by activation of the D2/3 receptors in the mPFC. Clozapine tolerance expression relies on the neuroplasticity initiated by its antagonist action against 5-HT2A/2C receptors in the mPFC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25288514      PMCID: PMC4361252          DOI: 10.1007/s00213-014-3756-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

1.  Differential tolerance to the behavioral effects of chronic pimozide and clozapine on multiple random interval responding in rats.

Authors:  H.F. Villanueva; J.H. Porter
Journal:  Behav Pharmacol       Date:  1993-06       Impact factor: 2.293

2.  Fear and feeding in the nucleus accumbens shell: rostrocaudal segregation of GABA-elicited defensive behavior versus eating behavior.

Authors:  S M Reynolds; K C Berridge
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

3.  Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.

Authors:  Tao Sun; Gang Hu; Ming Li
Journal:  Eur J Pharmacol       Date:  2008-11-27       Impact factor: 4.432

4.  Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats.

Authors:  Andrew J Goudie; Jon C Cole; Harry R Sumnall
Journal:  Behav Pharmacol       Date:  2007-02       Impact factor: 2.293

5.  Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation.

Authors:  C D Young; M Bubser; H Y Meltzer; A Y Deutch
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

6.  Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.

Authors:  Rongyin Qin; Yingzhu Chen; Ming Li
Journal:  Neuropharmacology       Date:  2013-08-14       Impact factor: 5.250

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

8.  Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs.

Authors:  F I Tarazi; S K Yeghiayan; J L Neumeyer; R J Baldessarini
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1998-05       Impact factor: 5.067

9.  Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats.

Authors:  F J Wan; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors.

Authors:  Pablo Vázquez-Borsetti; Roser Cortés; Francesc Artigas
Journal:  Cereb Cortex       Date:  2008-11-21       Impact factor: 5.357

View more
  5 in total

1.  Behavioral, pharmacological and neuroanatomical analysis of serotonin 2C receptor agonism on maternal behavior in rats.

Authors:  Ruiyong Wu; Jun Gao; Shinnyi Chou; Collin Davis; Ming Li
Journal:  Psychoneuroendocrinology       Date:  2016-08-16       Impact factor: 4.905

2.  Activation of 5-HT2A receptor disrupts rat maternal behavior.

Authors:  Jun Gao; Ruiyong Wu; Collin Davis; Ming Li
Journal:  Neuropharmacology       Date:  2017-09-28       Impact factor: 5.250

3.  GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice.

Authors:  Brend Ray-Sea Hsu; Shin-Huei Fu
Journal:  Toxicol Rep       Date:  2016-04-27

4.  Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics.

Authors:  Lanchang Gao; Chao Hao; Ru Ma; Jiali Chen; Guisen Zhang; Yin Chen
Journal:  RSC Adv       Date:  2021-05-07       Impact factor: 4.036

Review 5.  Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms.

Authors:  Ming Li
Journal:  J Psychopharmacol       Date:  2016-07-01       Impact factor: 4.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.